Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AAOS News: Orthobond to Unveil Antimicrobial Surface Tech - Orthopedic Design & Technology
OEM News, Supplier News

AAOS News: Orthobond to Unveil Antimicrobial Surface Tech

Eliminates microbes on metallic and polymeric surfaces.

Orthobond announced its patented antimicrobial nanosurface technology will be unveiled at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in San Diego, September 1 through 3. Orthobond’s surface technology is the only non-eluting and non-antibiotic treatment designed for medical implants. The company is completing safety and efficacy testing for FDA marketing submission in late 2021.
 
Contamination has a serious impact on patient care, and Orthobond’s technology has the potential to improve outcomes with medical devices, such as implants and instruments in orthopedics, plastic surgery, cardiovascular and other implantable device areas. Orthobond’s antimicrobial nanosurface treatment is designed to kill viruses, bacteria and fungi by rupturing the pathogen.
 
“The world is focused on pathogens more than ever, and we understand the need for protection,” said David Nichols, CEO of Orthobond. “Orthobond’s technology creates a covalently bound nanosurface that is designed to kill bacteria, viruses and fungi, yet is safe for human contact. Our first products will be a series of antimicrobial medical device surface treatments designed to protect from pathogens without the use of drugs or eluting chemicals, but long term we see broad applications for textiles, consumer goods and high-touch areas in public places.”
 
The Orthobond team has worked for over a decade to improve patient outcomes by developing technologies that aim to kill pathogens. In the process, Orthobond has tested over a thousand different linker-agent combinations to create the best solution, unlike anything that is currently on the market. Orthobond’s technology makes use of powerful covalent linker technology that presents a highly efficacious antimicrobial with broad-spectrum activity directly on the device surface.
 
The Orthobond team will be at AAOS at the San Diego Convention Center in booth number 4050. For all business inquiries, email Chuck Reynolds, reynoldsc@orthobond.com; for press interested in meeting at AAOS or for further info, email Amber Stafford, amber@neilsonswiader.com.

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters